N-(4-(5-((dimethylamino)methyl)-1-methyl-1H-pyrazol-3-yl)pyrimidin-2-yl)-1-methyl-3-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-indazol-5-amine

ID: ALA4784088

Chembl Id: CHEMBL4784088

PubChem CID: 162666018

Max Phase: Preclinical

Molecular Formula: C22H24N10O

Molecular Weight: 444.50

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1nnc(-c2nn(C)c3ccc(Nc4nccc(-c5cc(CN(C)C)n(C)n5)n4)cc23)o1

Standard InChI:  InChI=1S/C22H24N10O/c1-13-26-27-21(33-13)20-16-10-14(6-7-19(16)32(5)29-20)24-22-23-9-8-17(25-22)18-11-15(12-30(2)3)31(4)28-18/h6-11H,12H2,1-5H3,(H,23,24,25)

Standard InChI Key:  VCLGWEJYKWKPFX-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4784088

    ---

Associated Targets(Human)

SYK Tclin Tyrosine-protein kinase SYK (7372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SU-DHL-2 (105 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 444.50Molecular Weight (Monoisotopic): 444.2135AlogP: 2.93#Rotatable Bonds: 6
Polar Surface Area: 115.61Molecular Species: NEUTRALHBA: 11HBD: 1
#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 12.52CX Basic pKa: 7.60CX LogP: 1.84CX LogD: 1.42
Aromatic Rings: 5Heavy Atoms: 33QED Weighted: 0.42Np Likeness Score: -1.67

References

1. Grimster NP,Gingipalli L,Barlaam B,Su Q,Zheng X,Watson D,Wang H,Simpson I,Pike A,Balazs A,Boiko S,Ikeda TP,Impastato AC,Jones NH,Kawatkar S,Kemmitt P,Lamont S,Patel J,Read J,Sarkar U,Sha L,Tomlinson RC,Wang H,Wilson DM,Zehnder TE,Wang L,Wang P,Goldberg FW,Shao W,Fawell S,Dry H,Dowling JE,Edmondson SD.  (2020)  Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.,  30  (19): [PMID:32717371] [10.1016/j.bmcl.2020.127433]

Source